The core output of a gene annotation project could be described as an in silico transcriptome: a collection of 'models' referred to in this Review as a genebuild. However, genebuilds are found in a data server, not in the cell: they are only representations of the tran scriptome that exists in nature. This fact has important implications for the study of biology: gene annotation is a key mechanism through which information is lever aged from genome sequences, and deficiencies in gene builds will be propagated into downstream analyses. Thus, how close are our genebuilds to actual transcrip tomes? Every publication seems to describe an entity that is larger, more dynamic and more functionally diverse than previously thought (as illustrated in FIG. 1) and this picture becomes even more complicated when considering the genomic sequences that regulate genes. In fact, the sheer complexity of the transcriptome may cause one to ask whether it is even possible that it could ever be completely described in silico. However, we are begging the question of whether we actually need to fully capture this complexity. A key annotation question concerns the proportion of the transcriptome that con tributes to cellular function, and it could be argued that the goal of annotation projects should be to describe only this 'functional transcriptome': to extract the signal from the noise.
In this Review, we discuss the current state of play in higher eukaryotic gene annotation, and attempt to take genebuilds out of the 'black box' for the benefit of annotation users. Throughout, we use an updated defi nition of the term 'gene' , beyond the traditional protein coding criterion, as described further in REF. 1 . First, we explain the key principles by which these resources are made, and why annotation projects are proceeding along alternative lines for different genomes. Inevitably, more work has been carried out on the human genome than any other, and many aspects of genome annotation are most effectively explained in this context. However, although human workflows are frequently reused in the description of other genomes, such projects are not truly analogous. This is because their scientific goals are often substantially different -typically more limi ted in scope -but also because the resources avail able to support annotation have changed dramatically in recent years. Second, even human genebuilds have 'blind spots' , and we wish to help users appreciate the biological information that is missing in such resources and how this can affect their work. The missing infor mation generally reflects biological questions that remain unanswered, in particular, the issue of transcript functionality. Nonetheless, our biological understand ing of the transcriptome is developing rapidly, and leaps in understanding are also being made in neighbouring fields of molecular biology, including proteomics, gene regulation and epigenomics. We explain below how gene annotation projects are coordinating efforts to combine such data sets into fully integrated views of genomic organization. Even so, it is clear that increas ing genebuild complexity presents a considerable prac tical challenge to scientists, and we end this Review by discussing the problems that are faced by annotation projects in improving their usability.
What is gene annotation? Annotation targets. FIGURE 2 summarizes the core principles of gene annotation workflows. Although numerous strategies have been used to describe differ ent genomes and gene features, each ultimately repre sents the unification of two processes. First, annotation defines the structure of a transcript -for example, its 
Functional annotation
The process of defining or predicting functional roles for transcript models during gene annotation.
Alternative splicing
Process by which a gene makes distinct transcripts through the use of different splice sites or exon combinations; these are known as alternative transcripts or transcript variants.
Pseudogenes
'Broken' genes that are derived from protein-coding loci. Can be formed by retrotransposition ('processed'), duplication ('unprocessed') or inactivation ('unitary', which may be polymorphic). All forms may be transcribed.
Long non-coding RNAs
(lncRNAs). Genes that do not contain protein-coding transcripts and that are not pseudogenes or small RNAs; a 200 bp size cut-off is typically applied to distinguish them from small RNAs.
Small RNA
A member of one of several known families of small RNA molecules. Includes the classic tRNA and rRNA families alongside more recent discoveries such as PIWI-interacting RNAs (piRNAs), microRNAs (mi RNAs) and small nucleolar RNAs (snoRNAs).
exon-intron architecture -and, second, it provides inferences into its potential function, for example, whether it is a proteincoding transcript. We refer to this second aspect as functional annotation. However, it is vital to appreciate that gene and transcript are not equivalent terms in annotation. This is illustrated by the fact that most genes generate multiple, distinct RNAs, especially through alternative splicing 2 . Transcripts are the major target of annotation projects; we regard 'gene annotation' as a process that creates 'transcript models' . As we discuss below, our modern understanding of transcriptional complexity within genes is driving the evolution of annotation strategies, as is the knowledge that eukaryotic genomes contain not only protein coding genes, but also pseudogenes and long non-coding RNAs (lncRNAs), as well as small RNA families, includ ing transfer RNAs, PIWIinteracting RNAs (piRNAs) and small nucleolar RNAs (snoRNAs) 3 . They may even contain RNA categories that remain to be discovered. In short, this complexity presents a substantial challenge to annotation projects (FIG. 1) .
Annotation strategies. Numerous factors come into play when choosing an annotation strategy for a genome (FIGS 2, 3) . Obviously, financial considera tions can place major constraints on the availability of human resources and computational power, as well as on the generation of experimental data to provide evidence for model construction
. However, the strategy also depends on what it is hoped to achieve. For our species, genebuilds support scientific enquir ies across a broad range of disciplines, and annota tion resources are required to be as comprehensive as possible. The same is true for projects using classic laboratory species, such as Mus musculus, Arabidopsis thaliana, Caenorhabditis elegans and Drosophila melanogaster. Other genomes may be sequenced to ask more specific scientific questions. For example, a com mon goal of sequencing projects within evolutionary biology is to find genes that have been subjected to positive selection. In this scenario, a high premium is placed on the identification of proteincoding sequences; features such as pseudogenes and small RNAs may even be completely ignored. Meanwhile, the Functional Annotation of Animal Genomes (FAANG) consortium plans to sequence and annotate livestock genomes in order to further our understanding of quantitative phenotypes 4 . Of course, it is broadly true that the more valu able a genome is to the scientific community, the more resources have been committed to its annotation. Therefore, humans 2,5 , mice 6, 7 , A. thaliana 8 , C. elegans 9 and D. melanogaster 10 have each been subjected to large scale annotation projects over many years, involving numerous scientific institutes and sequencing centres (TABLE 1) . In fact, the human and mouse genomes even have overlapping annotation resources that are inde pendently produced, such as the genebuilds created by the RefSeq 5, 6 and GENCODE 2,7 projects. Finally, we note that genome quality is an important factor when strat egizing. One cannot create highquality genebuilds using poorquality genomes, and even modest genome assembly improvements can be massively beneficial to annotation projects, as demonstrated for the honeybee 11 . Indeed, annotation and sequencing have been carried out for both human and model organism genomes in a reciprocal manner, and we refer to them throughout as 'reference' genomes and genebuilds (FIGS 2,3) . Nature Reviews | Genetics Locus a also has an associated retained intron, and an additional 'read-through' transcript incorporates exons from both gene a and gene b. This transcript is subjected to nonsense-mediated decay (NMD; unfilled lilac boxes). Gene c is a long non-coding RNA (lncRNA) with two transcripts (red boxes), although three small RNAs are also transcribed from within one of its introns (open blue boxes). Locus d and locus e are unprocessed (filled green boxes) and processed (grey box) pseudogenes, respectively. Locus d is transcribed. A series of promoter regions (filled grey ovals) and enhancer regions (pale grey ovals) are indicated. Promoters are associated with transcription start sites for the various loci, whereas enhancers may be found some distance from the gene or genes that they regulate.
Coding sequences (CDSs). The regions of a transcript that are translated, that is, contain the information that encodes a protein sequence.
Annotation evidence. Regardless of the scientific context of an annotation project, the most important factors to influence the genebuild that is produced are the evidence and methodologies that are used for model construc tion (BOX 2; FIGS 2,3). It is informative to consider how these elements have changed as reference annotation projects have become outnumbered by nonreference projects. In terms of evidence, the obvious difference is that Sangerbased transcript sequencing has been super seded by shortread RNA sequencing (RNAseq) 12 . Thus, although the bulk of models in reference genebuilds were constructed on cDNA or expressed sequence tag (EST) evidence, such libraries are typically absent for other genomes. This fact is important when it comes to anno tation. Most obviously, although RNAseq is cheaper and more high throughput than earlier protocols, the RNA sequences obtained are shorter and more prone to error. This creates notable problems for annotation, as we dis cuss below, and it still remains easier to build accurate models on longer RNA sequences.
The second key source of evidence is protein sequences, but this situation is more complicated, as the field of experimental protein sequencing lags far behind that for RNA or DNA sequencing. Thus, the earliest annotation projects described coding sequences (CDSs) based on curated protein sequences from SwissProt 13 ( . b | Protein-coding genes within non-reference genomes are usually annotated based on fewer resources; in this case, RNA sequencing (RNA-seq) data are used in combination with protein homology information that has been extrapolated from a closely related genome. RNA-seq pipelines for read alignment include STAR 130 and TopHat
131
, whereas model creation is commonly carried out by Cufflinks
23
. c | Long non-coding RNA (lncRNA) structures can be annotated in a similar manner to protein-coding transcripts (parts a and b), although coding potential must be ruled out. This is typically done by examining sequence conservation with PhyloCSF 132 or using experimental data sets, such as mass spectrometry or ribosome profiling. In this example, 5′ Cap Analysis of Gene Expression (CAGE) 46 and polyA-seq data 47 are also incorporated to obtain true transcript end points. Designated lncRNA pipelines include PLAR 49 . d | Small RNAs are typically added to genebuilds by mining repositories such as RFAM 133 or miRBase 134 . However, these entries can be used to search for additional loci based on homology. e | Pseudogene annotation is based on the identification of loci with protein homology to either paralogous or orthologous protein-coding genes. Computational annotation pipelines include PseudoPipe 53 , although manual annotation is more accurate 54 . Finally, all annotation methods can be thwarted by the existence of sequence gaps in the genome assembly (right-angled arrow). EST, expressed sequence tag.
Manual annotation
When a person constructs a transcript model de novo after appraising the available evidence (typically using software tools), or examines and potentially validates ('curates') a model that has been created computationally.
Computational annotation
The process of generating genebuilds through entirely in silico processes, that is, by the use of computational algorithms.
genomes still lack substantial numbers of high quality protein sequences, although ORFfinder efficacy has markedly increased as more genome sequences have become available. This is because a powerful way to find CDSs is through the ratio of synonymous to non synonymous substitutions within a prospective ORF 16 ; that is, to identify regions of DNA that are evolving as a proteincoding sequence.
Annotation workflows. The annotation 'workflow' chosen illustrates a second key difference between reference and nonreference genebuilds. Whereas all whole genome annotation is highly dependent on computational processing, the projects for reference genomes have supplemented these processes with man ual analysis. Generally, this involves teams of curators who either create transcript models from scratch, or else curate sets of computationally generated models 2, 5, [8] [9] [10] , and can involve interactions with external groups such as UniProt 13 or gene nomenclature committees 17 . Manual annotation is regarded as the gold standard 18 , and is one of the core workflows that allows genebuilds to be classified as 'mature' when performed to a significant degree (FIG. 3) . Nonetheless, such labourintensive work cannot cope with the number of species genomes that are becoming available, and most new genebuilds are generated entirely in silico.
Computational annotation has three core processes, depending on the resources available (FIG. 2) . The first process is based on the alignment of transcript evi dence. The second process is comparative annotation, by which the evolutionary closeness of two species allows for annotation -commonly the CDSs -to be 'projected' from one genome to another, or for evidence from one species to be used to build models on another. The third process is ab initio annotation, through which By contrast, novel genebuilds are constructed based on RNA-seq and/or ab initio modelling, in combination with the projection of annotation from other species (which is known as liftover) and the use of other species evidence sets. In fact, certain novel genebuilds such as those of pigs and rats now incorporate a modest amount of manual annotation, and could perhaps be described as 'intermediate' in status between 'novel' and 'reference'. Furthermore, such genebuilds have also been improved by community annotation; this process typically follows the manual annotation workflows for reference genomes, although on a smaller scale. Although all reference genebuilds are 'mature' in our view, progress into the 'extended genebuild' phase is most advanced for humans. A promoter is indicated by the blue circle, an enhancer is indicated by the orange circle, and binding sites for transcription factors (TFs) or RNA-binding proteins (RBPs) are shown as orange triangles. Gene expression can be analysed on any genebuild regardless of quality, although it is more effective when applied to accurate transcript catalogues. Clearly, the results of expression analyses have the potential to reciprocally improve the efficacy of genebuilds, although it remains to be seen how this will be achieved in practice (indicated by the question mark). 3D, three-dimensional; EST, expressed sequence tag. Nature Reviews | Genetics algorithmbased 'gene finders' such as GENSCAN 15 or AUGUSTUS 14 construct models on the basis of a priori knowledge of their likely sequence. Pure ab initio anno tation is actually now uncommon in higher eukaryotic genomes, and these strategies are most often used in combination. The RefSeq Gnomon pipeline is a modi fied form of GENSCAN that can perform purely ab initio annotation, although it can also integrate RNA and protein homology data when available (see The NCBI Eukaryotic Genome Annotation Pipeline). Ensembl have adapted their pipeline in a similar manner, and the less speciesspecific evidence that is available for a given genome, the more annotation will be based on a combi nation of projection and ab initio modelling. Similarly, WormBase are combining projection from C. elegans with ab initio modelling in the annotation of other nematode genomes 9 .
Even the largest annotation projects cannot yet describe genomes by the thousand, and researchers must often produce their own genebuilds. The Avian Genome Consortium, which aims to describe hundreds of bird genomes, is achieving this by working closely with Ensembl 19 . Annotation is being generated by the Beijing Genome Institute through the projection of existing bird and human Ensembl models, and is displayed in Avianbase, a modified form of the Ensembl schema 20 . RefSeq have also worked with external collaborators on specific genebuilds 5 . For researchers with fewer resources, numerous software tools can be used to carry out truly independent gene annotation. AUGUSTUS remains a popular choice; although it was developed as an ab initio tool for the Human Genome Project, its modern incarnation can incorporate transcript libraries and comparative evidence, albeit with a cost in terms of 
Cap Analysis of Gene Expression (CAGE).
Produces enormous ~27 bp fragment libraries extracted from the 5ʹ capped end of whole transcriptome RNA molecules when coupled to next-generation sequencing platforms 122 .
RNA Annotation and Mapping of Promoters for Analysis of Gene Expression (RAMPAGE)

123
. Similar to CAGE, although provides longer paired-end reads as opposed to short sequence tags, with the size dependent on the short-read RNA-seq platform used.
PolyA-seq. Captures RNA sequence immediately upstream of the polyA tail. The protocol reported by Derti et al. 47 generates amplicons of 200-500 bp, although the size of the tags obtained will depend on the sequencing strategy used.
CaptureSeq. Uses strategically designed oligonucleotide probes to pull down target RNA from a sample. The captured RNAs can be sequenced using any common platform 44 .
Functionality
Mass spectrometry (MS).
Most commonly applied through the combination of liquid chromatography and tandem MS/MS, which produces large numbers of peptide spectral graphs based on their mass-to-charge ratio. Spectra are typically interpreted by comparison against a set of theoretical peptides extrapolated from an in silico coding sequence (CDS) database 75 .
Ribosome profiling (RP).
Identifies regions of transcripts that are undergoing translation. Cellular RNA is chemically degraded, allowing for RNA fragments that are 'protected' by ribosome binding to be recovered for high-throughput sequencing 81, 82 . Also known as 'Ribo-seq'.
Ultraviolet (UV) crosslinking immunoprecipitation followed by sequencing (CLIP-seq).
Ribosome-binding proteins are bound to their target RNAs, which are recovered and subjected to high-throughput sequencing 99 . It has the resolution to reveal binding sites within the RNA.
The extended gene
Hi-C. A massively high-throughput version of chromosome conformation capture methodologies. DNA is crosslinked across the sites of chromosome loops using chemical treatment, and these linkage sites are recovered and sequenced on next-generation sequencing platforms 105 .
Chromatin Interaction Analysis Paired-end Tag Sequencing (ChIA-PET).
An adapted form of Hi-C that enriches for specific DNA-protein complexes using chromatin immunoprecipitation followed by sequencing (ChIP-seq). It can thus be used to investigate the role of specific proteins in chromosome looping 124 .
ChIP-seq. A method for analysing DNA-protein interactions in a cell 125 . It produces libraries of target DNA sites that are bound to a protein of interest, which are then mapped back to the genome to identify protein-binding regions. 14, 21, 22 . For such practical reasons, researchers often annotate their genome using a simpler RNAseq assembly pipeline such as Cufflinks 23 . Besides suffering from the RNAseq assembly problems dis cussed below, such methods are severely limited by the fact that they do not produce true functional annotation (see below), and, in common with ab initio builders, will typically generate a single model per gene. We do not regard these catalogues as true genebuilds.
Community annotation. For genomes such as that of the rat it has become clear that computational genebuilds cannot meet the needs of the community, and yet ade quate resources are not available to follow the RefSeq or GENCODE reference annotation model. One solution is to manually improve the annotation in a systematic, collaborative manner based on 'crowdsourcing' (REF. 24) (FIG. 3) . Either the interested parties meet in person and carry out a large amount of annotation over a short period of time (known as a 'jamboree') 25 , or else they work remotely over a longer of period of time, following the same annotation criteria 26 and using software such as WebApollo, which allows for 'live' annotation to be shared remotely 27 . This remote working strategy has been central to the annotation efforts of VectorBase, which is a community effort that seeks to describe the genomes of invertebrates that transmit disease to humans 28 . Nonetheless, the output of most projects cannot match reference curation teams in scale, and the focus is often limited to a particular biological theme, for example, the annotation of porcine immunologyrelated genes 29 .
Annotation in population genomics. It is now com monplace to generate multiple genome sequences from the same species, especially to aid the study of vari ation. Human studies have inevitably led the way, with projects such as the UK10K generating genomes by the thousands 30 , although 'population genomics' has now been carried out for species as diverse as rice 31 and killer whales 32 . Do these genomes require annotation?
If DNA variation is of primary interest, single nucleo tide polymorphisms (SNPs) can simply be extracted and displayed against the main assembly for that spe cies. Furthermore, if users wish to 'browse' additional genomes then transcript models can be projected from the main assembly. Projection is part of the annotation strategy of the Mouse Genomes Project (MGP) -which has released 36 genome sequences of laboratory mice and wildderived strains -in combination with ab initio modelling 33 . Nonetheless, the MGP also illustrates scenarios for which manual intervention is desirable. For example, when genes do not successfully project then manual curation can resolve whether this is due to variation or to genome sequence error 7 , and it can also be used to judge the quality of ab initio models. Manual annota tion can also be essential when investigating structural variants (SVs), which are of great interest to biologists owing to their association with disease and evolution 34 . The Genome Reference Consortium (GRC) continue to improve the human and mouse genome assemblies, and have created a series of 'alternative (alt) loci' for both species that target allelic variation, as well as SV regions containing genes that are subject to copy number vari ation (CNV) 35 . For example, the GRCh38 human genome assembly contains eight haplotypes for the major histo compatibility complex (MHC) 36 and 35 for the leuko cyte receptor complex (LRC) 37 . The interpretation of CNV gene families can be difficult: gene copies are often highly similar or even identical, and a proteincoding gene in one genome may be pseudogenized in another. It is impossible to simply extract this information for dis play against a reference genome, and such regions can be difficult to resolve without manual intervention.
When is a genebuild complete? Identifying missing transcripts. Having discussed pro gress in gene annotation, we now turn our attention to the limitations of existing genebuilds. Users should understand that even human genebuilds are works in 
Polyadenylation tail
A sequence of adenosine monophosphates attached to the 3ʹ end of an RNA as transcription terminates, beginning at the polyA site.
progress, and we now consider how far into the distance the finishing line for such endeavours might be found. Logically, a complete genebuild would contain all the transcripts that a genome produces, with accurate func tional information attached to each model. Certainly, an attempt to identify all the transcripts produced by a genome may be considered a key goal in the generation of a mature genebuild (FIG. 3) 40 . The most common protocols generate short reads that are less than 200 bp in size
, which is far shorter than the average mRNA. Reads are aggregated to predict fulllength transcripts, although this process is challenging 12 . RNAseq models are emphatically predictions, and have not been incorpo rated wholesale into most reference genebuilds owing to quality concerns 41 . As noted above, RNAseq models have instead proved a frequent necessity for annotat ing genomes that lack Sangersequenced transcript libraries. Meanwhile, longread RNAseq libraries are becoming available to improve annotation
. It is easier to align longer reads with accuracy, although the sequen cing quality is still not comparable to that of Sanger protocols 42 . An interesting development is syn thetic longread (SLR)seq, which circumnavigates the problem of shortread transcript assembly by generating synthetic long reads through the reconstruction of frac tionated and barcoded short RNA fragments 43 . Efforts are also being made to complete transcript catalogues based on targeted methodologies. CaptureSeq involves the use of genomic hybridization arrays to 'pull down' portions of the transcriptome for sequencing 44 . It is effective at isolating transcripts that are expressed at low levels, which may otherwise be 'drowned out' in whole RNA assays 45 . CaptureSeq is typically used to identify novel genes (FIG. 4) and to target partial models for com pletion. The experimental setup is laborious, however, and its use is currently limited to humans and mice.
Annotating transcript end points. How can one tell whether a model is precisely full length, that is, whether it contains the transcription start site (TSS) and transcript end site (TES) of the RNA? TESs can be identified from the 3ʹ polyadenylation tail, although there is no consistent
Box 2 | Defining functionality within the genome and transcriptome
There has been much debate about the proportion of the eukaryotic genome that is truly functional, generally through disagreements on how 'functionality' should actually be defined. Evolutionary biologists have traditionally placed a high value on the maxim that 'conservation equals function', and may thus doubt the functionality of non-conserved bases 87 . More recently, human experimental biology projects such as ENCODE have used a biochemical definition that is based on the use of high-throughput assays, including RNA-seq and immunoprecipitation techniques 104 . However, the proportion of the genome that participates in transcription and epigenomics is far larger than that which displays conservation, hence these definitions seem to be irreconcilable. The process of genome annotation can provide useful insights into this debate, as it approaches things from a different direction. In this case, the initial focus is not on individual base pairs, but on whole sequence elements such as transcripts, and it is of course transcripts that are the primary effectors of genomic information. The question can thus be restated as: which transcripts are functional and how do they function? In this context, the word 'functional' primarily concerns the role of the transcript in the cell; whether it is translated, for example, or whether it actually makes no contribution to physiology. It would thus seem reasonable to describe an mRNA as a 'functional transcript', and to describe a transcript that is simply stochastic noise as 'non-functional'. The more challenging ground is found between these two poles. For example, it is debatable whether the AIRN long non-coding RNA (lncRNA) transcript is a functional molecule given that it is ultimately a by-product of a regulatory pathway 93 , and the same question could be asked of regulatory non-productive transcripts (NPTs) that are found within protein-coding genes. Certainly, the generation of these transcripts directly mediates functional processes, and for this reason we prefer to regard them as functional molecules.
The question of how transcripts function, has in fact, a further layer of complexity. A typical mRNA contains various sequence features: most obviously the coding sequence (CDS), but potentially also regulatory sequences such as trans-factor binding sites, secondary structures and upstream open reading frames (uORFs). These are all potential targets for annotation, which suggests that we should regard an mRNA more properly as a 'functional transcript that contains a number of distinct functional features'. It is also interesting to note that mRNAs may contain sequences that are not functional according to the strict evolutionary definition; this is in fact more dramatically the case for well-studied lncRNAs such as HOTAIR 126 . Although this discussion may seem esoteric, it is actually of great practical importance. Gene annotation is of particular value in the clinic, where it is often used to aid the interpretation of disease-associated variants. A clinician would like to know not only that a given mutation is associated with a functional transcript, but also which sequence features it affects within that transcript. Although sequence conservation can be a useful aid to the prioritization of variants, annotation processes are ultimately required to convert such information into actual biological features.
Translation initiation site
(TIS). The codon that is translated to give the first amino acid of a peptide; almost always ATG; also known as a START codon.
STOP codon
The final codon of a protein translation; almost always TAG, TAA or TGA; also known as a translation termination site or codon.
diagnostic sequence for the TSS so it is difficult to know whether a transcript is 5ʹ truncated. Such ambiguity is problematic, because confident functional annotation depends on accurate structures. Whereas a CDS may be obvious on a fulllength transcript, it could be missed on a truncated version, especially if sequencing has not encom passed the translation initiation site (TIS) or STOP codon. The implications of this are particularly concerning in disease genetics, where CDS annotation is the key data set through which identified genetic vari ants are inter preted. This problem seems to be solvable, however, given the advent of modified RNAseq assays to sequence end points
. Notably, FANTOM5 has generated millions of 5ʹ Cap Analysis of Gene Expression (CAGE) sequences from more than 400 tissues or cell lines for humans and mice 46 . Although the major goal of this project is to study transcript expression, these data are also proving highly useful for manual curation efforts 7, 40 (FIGS 2,3) . . Three transcription factor binding (TFB) regions -E2F1, E2F4 and E2F6 -colocalize based on ENCODE chromatin immunoprecipitation followed by sequencing (ChIP-seq) data 104 . In combination, these data suggest an 'extended gene model' for NRIP1, which may aid the interpretation of three genome-wide association study (GWAS) signals linked to Crohn disease (rs2823286, rs1297265 and rs1736020; shown as asterisks), as previously noted by Mifsud et al. . RNA-seq from Uhlen et al. 117 indicates differential expression, with use of the upstream exon apparently limited to the bone marrow (and adipose; not shown). This TSS is dominant in white blood cells, which are bone marrow-derived cells. RNA-seq and CAGE support a more general expression profile for the downstream first exon, with evidence of TSS variability.
Isoforms
Protein molecules that differ in their amino acid composition from other translations made from the same gene, for example, owing to alternative splicing.
Intron retention
Occurs when a transcript does not splice out one or more introns, that is, this sequence is left incorporated into the mature RNA.
However, genes display considerable variability in their end points 46, 47 -even within the same exon -which challenges our assumptions about the rela tionship between transcript models and cellular RNA. Annotation projects using these data sets can try to rep resent this diversity or else attempt to summarize it. The key issue is whether this complexity is biologically mean ingful. This may not be the case for end point 'wobble' , which could reflect stochastic variability in the binding of the RNA polymerase II or polyadenylation complexes. If a project favours simplicity, gene boundary data can be converted into single basepair sites and can be incorporated into computational workflows. For exam ple, Boley et al. used CAGE and polyAseq data in the generation of D. melanogaster RNAseqbased models 48 , and the PLAR pipeline incorporated polyAseq in the annotation of 17 vertebrate genomes 49 . However, differ ential end point usage can have important functional consequences, especially linked to gene regulation (as discussed below).
Functional annotation
When RNAseq protocols can produce accurate, full length transcripts then the need to curate these struc tures will diminish. Instead, the legacy of genebuilds is likely to be their functional annotation. Traditionally, functional annotation centred on the question of which models encode protein. We now know that non coding genes and untranslated transcripts can function in many different ways. Indeed, the definition of 'func tional' remains controversial in genomics, as we dis cuss in BOX 2. Nonetheless, a survey for proteincoding loci remains a common starting point for the anno tation of novel genomes, and efforts to annotate the complete set of translated regions are ongoing even in reference genebuilds.
Distinguishing protein-coding genes and pseudogenes. As discussed above, CDS annotation is typically based on the incorporation of curated protein sequences, as well the computational processing of protein homolo gies and conservation signals. However, a genuine sig nal does not confirm that a region is coding, rather it confirms that the region has been coding at some point in its history. This distinction is crucial, as eukary otic genomes contain large numbers of pseudogenes 50 (FIGS 1,2). Pseudogenes are a major confounding fac tor for computational CDS annotation: they may con tain large ORFs and are frequently transcribed, and duplicated or retrotransposed pseudo genes with high sequence similarity to the parent locus can compli cate both CDS projection and RNAseq mapping 51 . Even their manual interpretation is complicated, which is a major reason why GENCODE, RefSeq and UniProt do not agree on the number of human protein coding genes. For example, retrotransposition can gen erate intact copies of the parental CDS 52 , and whereas GENCODE have annotated more than 300 'retrogenes' as proteincoding, the functionality of those that do not exhibit conservation remains speculative. Alternatively, although duplicated copies of a parent gene may have disrupted CDS, it can be unclear whether this causes loss of function (LoF) 51 . These ambiguities are exacerbated in lower quality genome sequences: CDS disablements in prospective pseudogenes -and LoF mutations in rese quenced genomes -could instead be sequencing errors. Although there are a limited number of dedicated tools for the computational analysis of pseudogenes, including PseudoPipe 53 , manual annotation remains preferable 54 .
The coding potential of alternative splicing. A second complication in CDS annotation is that proteincoding genes can make distinct proteins (isoforms) through alter native splicing 55, 56 . However, although alternative spli cing is ubiquitous among multiexon genes, the extent to which it generates proteomic diversity is debatable 57, 58 . Indeed, it should be emphasized that the bulk of CDS annotation in eukaryotes is based on extrapolation as opposed to experimental evidence, and this fact is likely to have important implications across the field of biology. Certainly, alternative splicing does not always generate isoforms, and we refer here to transcripts from protein coding genes that do not generate mature proteins as nonproductive transcripts (NPTs). Distinguishing cod ing transcripts and NPTs is a major goal of maturing annotation projects 40 , although RefSeq and GENCODE approach the problem from different directions. RefSeq have trad itionally focused on models that are considered likely to be protein coding on the basis of additional evidence, for example, from SwissProt. GENCODE annotate such models along similar lines; however, they ultimately aim to provide functional annotation for all identified transcripts. The coding potential of these addi tional transcripts is judged in comparison with a model within the gene that is known to be protein coding. Thus, an exonskipping transcript is likely to be annotated as coding if it does not contain a frameshift. Such first principlesbased annotations are speculative. However, GENCODE reappraise their human CDS based on scor ing that is provided by the annotation of principal and alternative splice isoforms (APPRIS) pipeline 59 , which combines CDS conservation with predictions into the effects of alternative splicing on known protein domains. APPRIS has generated annotation for six mammals, as well as C. elegans and D. melanogaster. Finally, we note that GENCODE and RefSeq are in fact collaborating on the ongoing Consensus CDS (CCDS) project, the core goal of which is to produce CDS sets that are unified between different annotation projects 60 (TABLE 1) .
Non-productive transcription and untranslated regions in protein-coding genes. If transcripts within protein coding genes do not make proteins, what do they do? All cellular machines are errorprone, and intron retention (IR), for example, could simply be due to splice osome failure 40, 57 . Furthermore, the sequence motifs that gov ern transcription, splicing and translation are typically basic, and 'cryptic' sites throughout the genome can act as competitors to canonical sites. Such knowledge recontextualizes the question of when a transcript cata logue is complete, and it is generally accepted that a pro portion of the transcriptome is aberrant 'noise' , although Nonsense-mediated decay (NMD). Cellular 'surveillance' mechanism that targets transcripts for destruction. Imprecisely understood, although transcripts featuring termination codons more than 50 bp upstream of splice junctions are thought likely to be substrates.
Poison exon
An exon that prevents correct coding sequence translation when incorporated into the transcript of a protein-coding gene, either by causing a frameshift or through the introduction of a premature termination codon.
Untranslated region
(UTR). Non-coding sequence on coding sequence transcripts found between the transcription start site and the translation initiation site (5ʹ UTR), and the STOP codon and polyA site (3ʹ UTR).
the size of this proportion is debated 57, [61] [62] [63] [64] . However, NPTs can impart gene regulation. Many proteincoding genes reduce their protein output not by 'switching off ' , but by directing their transcription into non productive pathways. The best characterized mechanism by which this occurs is alternative splicinglinked nonsensemediated decay (NMD) 65 . Although NMD was originally understood as a mechanism for the degradation of aber rant transcripts, many genes use this pathway to dampen their output in a regulated manner 66 , typically through the splicing of a poison exon that contains a termination codon. Regulation can also be imparted through intron retention, which is emerging as a key control mechanism in haematopoiesis 67 . In fact, up to threequarters of mam malian genes exhibit systematic intron retention, especi ally in cell types in which expression is not anticipated; intron retention may be 'functionally tuning' these cells 68 .
The contribution of intron retention to gene regulation is particularly well established in A. thaliana 39 . Regulatory NPTs can also be invoked through differential TSS usage, although in this scenario the transcripts are potentially less productive rather than non productive. For example, the human granulin (GRN) gene produces two transcripts that have highly different rates of translation, even though they have the same CDS 69 . The weakly translated form has a longer 5ʹ untranslated region (UTR), which incorporates a short upstream ORF (uORF) that competes for ribosome binding with the regular CDS. TSS switching to the short 5ʹ UTR form thus increases protein production. Most human and mouse first exons contain multiple TSS regions according to FANTOM 46 , and most 5ʹ UTRs con tain uORFs (J.M.M. and J.H., unpublished observations). Could transcripts that differ in their 5ʹ UTRs have pre cisely the same translational efficiency? The regulatory importance of uORFs is certainly recognized 70 , although they remain a blind spot for even reference genebuilds.
The situation for differential TES use is at least super ficially similar, and there is evidence that this process can modulate RNA stability and localization by creating transcripts that differ in their secondary structure or in their response to trans factors 71, 72 . Just as for TSSs, anno tation projects generally extend models to the maximum 3ʹ distance that is supported by transcriptional evidence, and do not annotate additional models based solely on alternative TESs.
NPTs are not simply a latestage target for mature genebuilds; such transcripts will also be sucked into the annotation pipelines for novel genebuilds, and are at risk of misannotation. Nonetheless, if such knowledge could be captured it may radically change the way users perceive their genes of interest. An obvious question is how to distinguish models that invoke NPTs as part of regulatory programmes from those that arise as sto chastic noise. Currently, this is being achieved through lowthroughput laboratory studies, and it is notable that the differential TSS usage in GRN is currently not represented in GENCODE or RefSeq. However, global insights can sometimes be gained from com parative analyses; poison exons, for example, are often highly conserved in vertebrates 66, 73 . It may be that the blueprints for such phenomena can ultimately be read in the genome, for example, in the form of binding sites for transacting factors 74 .
Annotating proteins with experimental data. CDS annotation is interpretive because the chemistry of the protein molecule makes it far less amenable than RNA to sequencing. However, recent advances in mass spec trometry (MS) have given birth to proteogenomics: the identification of CDS through the integration of peptide data and genomic or transcriptomic sequences 75 . The experimental parameters for this emerging technique are still being established [76] [77] [78] [79] . Above all, it is a com pletely different paradigm from that of RNA sequencing
: peptide identification depends not on mapping, but on the correlation between the spectra that are observed in the experiment and those predicted to be produced within a CDS search space defined in silico. The design of this 'search space' has a substantial bear ing on the results, and the falsediscovery rates for pro teogenomics assays are notoriously difficult to gauge 75 . Peptides are also frequently too short to distinguish isoforms. Furthermore, not all proteins are amenable to MS owing to their chemistry or cellular location, and it is harder to capture proteins with low expres sion 75 . Nonetheless, the utility of this technique for CDS identification and validation is clear 80 . Ribosome profiling (RP) identifies RNA regions that are undergoing translation 81, 82 
. Currently, there is no community consensus on how RP data sets should be used in annotation, and there are technical questions remaining regarding their production and interpreta tion 83 . It seems that genuine RP regions do not neces sarily highlight actual CDSs, that is, that RNA-ribosome interactions do not always lead to the production of mature proteins 84 . This could be because certain inter actions are transient as opposed to truly functional 85 . Alternatively, there is evidence that lncRNAs and pro teincoding genes can use ribosome binding to impart regulation, for example, via NMD 65 . Nonetheless, others suspect that RP data sets truly identify significant num bers of typically small proteins that do not display con servation or homology to known proteins 86 . The concept of 'lineage specific' biology provokes strong opinions 87 , and this debate is important from an annotation per spective, for which conservation is a key proxy for func tionality. Although RP has been carried out on at least six other eukary otic genomes so far -as collated by the RPFdb resource 88 -these data have not yet been incor porated into the computational annotation pipelines of reference genomes.
LncRNA annotation. LncRNAs present challenges to annotation projects similar to those presented by NPTs; they can have functional roles in mammalian cells 89 , although it has been argued that many are transcrip tional noise 90 . Pertinently, lncRNAs are typically weakly conserved in comparison with CDSs, and show high evolutionary turnover 91, 92 . Nonetheless, it may be mis guided to judge lncRNA functionality solely by analogy to protein coding transcription, as the basepair
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Sequence that regulates a promoter from a distal site on the chromosome, probably brought into close proximity through DNA looping.
Promoters
Regions immediately upstream of the transcription start site where the RNA polymerase complex attaches in order to initiate transcription. content of these transcripts is not always coupled to their functionality in an obvious way. For example, the AIRN lncRNA regulates the activity of the insulinlike growth factor 2 receptor (IGF2R) locus on the oppo site strand not through the activity of its transcriptwhich is apparently a byproduct -but through the act of its transcription 93 . This emerging perspective on functionality represents a paradigm shift for annotation projects
.
It is difficult to infer lncRNA functionality through annotation alone; true understanding comes from the laboratory. Nonetheless, annotation does have an impor tant role in judging translation, and most lncRNA models within genebuilds (or those generated by pipelines such as PLAR 49 ) are simply transcripts that are not protein coding, pseudogenes or small RNAs. It may also be useful to subclassify models on the basis of their genomic location 94 . This could aid scientists in investi gating particular lncRNA categories; enhancerassociated elncRNAs, for example, are of interest in the field of regulatory genomics 95 , as is the bidirectional transcrip tion that is commonly observed from proteincoding gene promoters 96 . However, lncRNA functional anno tation may become more proactive: sequences such as microRNA binding sites 97 and RNA structures 98 are beginning to be described, and ultraviolet (UV) crosslinking immunoprecipitation followed by sequen cing (CLIPseq) can identify RNAs interacting with RNAbinding proteins 99 . In the meantime, genebuilds can incorporate laboratorygained knowledge of func tionality. LncRNAdb is a database that is attempting to catalogue functional lncRNAs on the basis of literature curation 100 . It currently contains entries for 287 lncRNAs from a variety of eukaryotic species. Other repositories seek to build larger consolidated lncRNA catalogues, including LNCipedia 101 , which focuses on human lncRNAs, and NONCODE 102 , which contains informa tion from 16 species. Meanwhile, the RNAcentral data base 103 contains 8.1 million RNA sequences, representing all major functional classes of noncoding RNAs from a selection of species; a key goal is to resolve the redun dancy between the lncRNA data sets produced from different annotation groups.
Annotating the extended gene
Human genetics is faced with a substantial problem: traitassociated variants are commonly found outside gene sequences and thus defy interpretation. Gene annotation projects are, therefore, turning their atten tion to the genomic elements that control gene activity, the best studied of which are promoters and enhancers. Both are controlled by transcription factor binding, and each has its own characteristic (albeit imprecisely understood) epigenomic profile. ENCODE especially has provided enormous data sets on these sequences, mostly through the use of immunoprecipitation tech niques 104 
. Furthermore, it has been known for decades that chromosomes exhibit 'loops' , which can indicate enhancer-promoter interactions. Modern assays such as HiC 105 and chromatin interaction ana lysis pairedend tag sequencing (ChIAPET) 106 capture the DNA fragments that flank these loops, allowing them to be mapped onto the genome as topologically associated domains (TADs). Such data sets offer the potential to create 'extended gene' models, as illustrated for nuclear receptor interact ing protein 1 (NRIP1) in FIG. 4 . From a human perspec tive, an obvious benefit of linking genes to regulatory elements is that it increases the space within which dis easeassociated variants can be interpreted, although it should be emphasized that such efforts are in their infancy. One problem is that HiC and ChIAPET high light enormous numbers of TADs (even when 'capture' methods are used to target known promoters 107 ), rais ing questions about the signal to noise ratio 105, 106 . This noise seems to be biological as well as artefactual 108 , and it is unclear what proportion of genuine TADs actu ally demarcate enhancers. Currently, the ENCODE enhancer sets -extrapolated from biochemical data 104 -are far larger than those that have been functionally validated in the laboratory 109 . The fact that gene regu lation is spatio temporal complicates the situation, and it is known that genes can be controlled by multiple enhancers, and enhancers can control multiple genes 110 . Extended genes would be more useful if they could also integrate the transcription factor binding sites that are found within enhancers and promoters. Transcription factor annotation has trad itionally proved difficult: binding motifs are typically short (~6 bp) and impre cise, thwarting genome mining efforts 111 . However, chromatin immuno precipitation followed by sequencing (ChIPseq) data sets are now available for dozens of tran scription factors, highlighting in vivo regions of DNA occupancy while allowing for more accurate consensus motifs to be deduced 112 . If such information can be com bined with chromosome conformation and chromatin immunoprecipitation data sets, more precise extended genes may be obtained. This has been well demonstrated for CTCF, a factor that is known to have a key role in loop formation 113, 114 . The challenge for genebuilds is how to integrate and display such data alongside their transcript models. A description of extended genes is a core goal of the developing ENCODE encyclopae dia resource, and tools to visualize threedimensional (3D) data sets on the genome, such as the 3D Genome Browser, are becoming available 112 .
Improving the usability of genebuilds
The incorporation of transcript expression data. As genebuilds provide more precise representations of the transcriptome, they inevitably become more complex. This point has important repercussions for users. For example, many scientists are focused on human BRCA1 owing to its association with breast cancer, and may wonder what to make of the fact that GENCODE has 30 transcript models of this gene, whereas RefSeq has six. In practice, human annotation resources especially are used in many different ways. Whereas some scien tists would like to use all the transcripts that are associ ated with a given gene -for example, when designing hypothesisdriven experiments within a single locus -a common desire is for simplification. In fact, users often wish to work with a single transcript model per gene in order to streamline the experimental design of wholetranscriptome studies. One way to achieve 'tran script prioritization' is by measuring RNA expression, that is, to identify the 'dominant' transcript in a gene. Although it remains challenging to resolve individual transcripts based on RNAseq, the fact that most human proteincoding genes have a dominant transcript indi cates that there is a value to expressionbased filtering 115 . However, dominance can 'switch' between cell types, and expression changes are typically analogue rather than simply 'on' or 'off ' (REFS 115-117 ). An additional point of considerable importance is that RNA is ultimately a proxy for the measurement of protein output within proteincoding genes. In reality, the relationship between RNA and protein output remains imprecisely under stood 118 , and correlations between the two are frequently weak 119 . Although this may have striking consequences for RNAbased expression studies, the maturing field of quantitative proteomics does not yet provide precise guidance for annotation projects.
The prioritization of functional transcripts. Currently, reference genebuilds do not explicitly highlight princi pal transcripts based on quantitative evidence, and the description of spatiotemporal expression comes instead from 'downstream' endeavours such as the GenotypeTissue Expression (GTEx) project 116 . One could anti cipate that such information will soon be leveraged in reference genebuilds, perhaps influencing how models are displayed in genome browsers. Nonetheless, there is a limit to what expression data alone can tell us about transcript functionality
: transcripts with lower expression are not necessarily nonfunctional (or even less functional), and the expression of numer ous genes in fact seems to be dominated by NPTs 115 . When it comes to genebuild usability, it is this ques tion of functionality that is of paramount importance, most obviously when it comes to CDS annotation. For example, it is important to predict the molecular and clinical consequences of variation within BRCA1, and the processing of variant data sets typically begins with a comparison against gene annotation 120 . This allows variants to be stratified according to their poten tial mechanistic consequences, such as whether they disrupt a CDS or fall within an intron.
Clearly, there is a close relationship between the quality of gene annotation and the accuracy of vari ant interpretation, and yet many aspects of annotation -especially functional annotation -remain puta tive. This is particularly true for genebuilds such as GENCODE, which attempt to annotate all transcripts. Putative functional annotation can introduce false positives into variantcalling workflows; for example, where LoF mutations are called in CDS exons that are not in reality coding. GENCODE attempts to reduce this problem by providing 'Basic': a ~50% reduced build in comparison to the 'Comprehensive' set, result ing especi ally from the removal of models with trun cated CDSs. As discussed above, GENCODE also uses APPRIS to highlight coding models of probable func tionality based on conservation 59 . By contrast, the use of smaller genebuilds could introduce false negatives into variant analyses, that is, where consequential variants are missed or misinterpreted because they fall outside the gene annotation. However, RefSeq allows users of its core genebuilds to work with sets of more prospective transcripts, in the form of its uncurated (XM) 'in silico' models. Finally, Ensembl and the National Center for Biotechnology Information (NCBI) are collaborating on the Locus Reference Genomic (LRG) project 121 . The remit of this work is to standardize the gene annotation that is used in the clinic, with a key aim being to select a set of transcript models for core disease genes. These models are manually selected, in order to include what seem to be the key functional elements for a given gene.
Conclusions
The complexity of gene annotation projects reflects the complexity that exists in eukaryotic cells, and, as we do not currently fully understand the transcrip tome, all of our genebuilds are incomplete. Current ambiguities are most keenly felt in our own species, where nothing less than a total understanding of biol ogy is demanded. For other projects, the 'finish line' may not be so far into the distance, and the length of journey taken will in many ways reflect the value of that genome to science. However, all genebuilds face challenges in how they present their resource to the public; most obviously, they must find ways to make sure that increasing complexity does not correlate with decreasing usability.
